American Society of Hirudotherapy

Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review

Research article published in Therapeutics and clinical risk management (2015)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewClinical TrialsMandernach et al. · Therapeutics and clinical risk management, 2015

Abstract

Venous thromboembolism (VTE) results in significant morbidity and mortality. The prevention and treatment of VTE is managed with anticoagulant therapy, historically parenteral anticoagulants such as unfractionated heparin, low molecular weight heparin, and fondaparinux, and oral vitamin K antagonists such as warfarin. In the last few years, several target-specific oral anticoagulants have been developed, including the direct thrombin inhibitor dabigatran and anti-Xa inhibitors rivaroxaban, apixaban, and edoxaban. The target-specific oral anticoagulants have proven to be noninferior to vitamin K antagonists and heparins in the prevention and treatment of VTE. This review will focus on the pharmacology, clinical trial data, and laboratory assessment of apixaban. Moreover, perioperative management, use in special populations, and management of bleeding complications in patients taking apixaban for the prevention and treatment of VTE will also be discussed.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview

Summary

Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.

Why This Matters for Hirudotherapy

This narrative review summarizes the pharmacology, clinical-trial data, perioperative use, and bleeding management of the oral anti-Xa inhibitor apixaban for preventing and treating venous thromboembolism, noting that target-specific oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban) have proven noninferior to vitamin K antagonists and heparins. For ASH it is general anticoagulation context only. Importantly, this is a naming/category collision: apixaban and the other agents discussed are synthetic small-molecule anticoagulants, NOT leech-derived molecules, so the site's framing of them as 'leech-derived' is inaccurate and the hirudotherapy relevance is low. Caveat: as a single narrative review of a synthetic drug, it provides no data on medicinal-leech therapy and should not be read as bearing on leech efficacy or safety.

Citation

Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review.

Mandernach et al. · Therapeutics and clinical risk management, 2015

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.